Breast Augmentation (Implants) | Breast Implant Illness and Implant-Associated Cancers

Reported symptoms include fatigue, brain fog, muscle or joint pain, rash, numbness or tingling, hair loss, memory or thinking problems, dry eyes or blurred vision, breast pain, food sensitivity, flu-like symptoms and breathing difficulty. The cause is probably multifactorial and may include psychosomatic factors; no cause-and-effect link between implants and BII has been proven. BII can occur with silicone or saline implants. There is no definitive timeline for onset, and concomitant diagnoses can complicate assessment. Some women report relief after implant removal, but improvement varies, and implants alone may not cause the illness. Patient complaints should be taken seriously and assessed individually.

ASPS lists systemic symptoms commonly referred to as breast implant illness, including fatigue, “brain fog,” muscle or joint pain and rash. A plastic surgery text describes BII as a wide range of symptoms, especially rheumatologic complaints such as fatigue, dizziness, myalgia, arthralgia and rash, with no specific diagnostic test; it is a cluster that does not fit another classic disease diagnosis. The mechanism is probably multifactorial, including psychosomatic factors, and silicone incompatibility has been associated with ASIA syndrome. In 2020, Wee and colleagues found implant removal relieved symptoms and identified additional symptoms such as numbness or tingling, hair loss, memory or cognitive problems, dry eyes or blurred vision, breast pain, food intolerance, flu-like symptoms or low-grade fever, and difficulty breathing.

Breast implant illness is not a confirmed diagnosis with a known mechanism; it describes symptoms some patients attribute to implants. Investigations are ongoing. The 1999 Institute of Medicine found insufficient evidence to implicate silicone implants in systemic illness, and additional studies confirmed this, although many women strongly believe implants caused their symptoms. ASPS lists fatigue among symptoms some patients attribute to implants, while noting most people with implants have no serious complications. If symptoms occur, patients should consult a plastic surgeon to address them in a timely manner. Fatigue can have many causes, so new or persistent fatigue after augmentation should be medically evaluated rather than assumed to be implant-related.

FDA lists systemic symptoms such as fatigue, brain fog, muscle or joint pain and rash among possible implant-related concerns, and some patients attribute them to implants. FDA-approved implants undergo extensive testing, and most people with implants have no serious complications. Yet the 1999 Institute of Medicine found insufficient evidence linking silicone implants to systemic illness, and later studies agreed. Investigations continue. If symptoms develop, timely evaluation matters. Some patients choose removal, which is their right, but expectations should be discussed, including possible extra skin, more scarring, less projection, no symptom resolution, and whether the capsule should be removed or kept.

Pain after augmentation can come from surgical trauma, implant size or placement, or technique. Women may feel pain of varying degrees and length of time following augmentation surgery, and studies show breast pain rates of 5–16% at 3 years and 7–17% at 5 years with saline implants. Studies have also shown that pain following augmentation surgery increases with time. Breast pain is common in women generally, so implants are not always the cause. Implant-related breast pain may also relate to tightening of scar tissue around the implant, calcification, nerve injury or compression, rupture, or muscle compression. If any complication develops, consult a plastic surgeon promptly.

Large meta-analyses and nationwide cohort studies found no significantly increased risk of any specific connective-tissue disease, all definite connective-tissue diseases combined, or other autoimmune or rheumatic conditions with silicone breast implants. Another review found no conclusive evidence of a significant increase in relative risk and suggested minimal, if any, population effect. Breast implant illness is poorly understood, with an unknown cause; patients may experience fatigue, difficulty concentrating, hair loss, weight change or depression. Epidemiological reviews report associations with Sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis, chronic fatigue syndrome and Raynaud’s syndrome. Two possible exceptions are scleroderma and ASIA. These findings do not rule out individual symptoms, so careful clinical assessment remains important.

Available information discusses hormonal changes as a factor that can increase breast volume or drooping over time, not as an effect of implants. It also describes hormone therapy in male breast augmentation as a separate treatment context. Implants are silicone or saline devices placed behind breast tissue or muscle. Hormonal changes can occur naturally with age, weight change, pregnancy, or menopause. They may alter breast size, shape, or ptosis independently of any implant. If you have menstrual, thyroid, mood or other body-wide symptoms, those should be evaluated medically rather than assumed to come from implants. This information is limited to these contexts, so it cannot settle every individual concern. Consultation helps.

Implants add a small amount of weight, but they do not create ongoing unexplained weight gain or loss. In one study, patients with implants had a mean weight gain of only 536 g, comparable to the weight of two implants, so body weight changes were not expected to systematically influence breast volume. Weight gain can make augmented breasts look larger or more ptotic, while weight loss can make implant edges or rippling more visible. These are appearance changes, not implant-caused weight changes. Implant placement and tissue coverage also influence how weight changes show on the chest. If your weight changes unexpectedly, medical causes should be evaluated separately rather than attributed to implants.

Breast implant illness describes nonspecific systemic complaints, commonly fatigue, memory or concentration difficulties, joint and muscle pain, hair loss, weight changes, anxiety, depression, rash, sleep disturbance and sicca symptoms. The FDA has acknowledged reports of these symptoms in women with all types of breast implants, regardless of filling material, shape or surface characteristics. BII is not currently recognized as a formal medical diagnosis, and no specific diagnostic test or validated criteria are available. Symptoms typically emerge five to thirteen years after implantation, though onset may occur at any point. One related mechanism is gel bleed, microscopic silicone leakage through an intact shell, linked to granulomatous inflammation and possibly systemic symptoms.

Breast implant illness is not well understood and is a cluster of symptoms that does not fit another classic diagnosis; it is not linked to abnormal physical or laboratory findings. Evaluation should begin by listening to concerns and performing a thorough physical and psychological assessment. Other reversible causes unrelated to implants should be ruled out, prior records reviewed, and routine tests such as complete blood count, metabolic panel, thyroid function, vitamin D and hormone evaluation considered. Breast imaging may be needed based on age, symptoms and findings, and serious or unevaluated symptoms should be referred to a primary care physician.

The term ranges from vague symptoms such as fatigue, brain fog, muscle or joint pain and rash to systemic illness, although evidence linking these problems to implants is limited. FDA-approved implants undergo extensive safety testing, and most people with implants have no serious complications. Reported risks include BIA-ALCL, BIA-SCC and systemic symptoms some patients attribute to implants. If a complication develops, patients should consult a plastic surgeon promptly; if removal is desired for any reason, they should also consult their surgeon. Evaluation should consider other possible causes before assuming implants are responsible. Patients should not assume implants are the cause without medical evaluation, and treatment decisions depend on symptoms, findings and patient goals.

Breast implant illness is a poorly understood symptom group—fatigue, “brain fog,” joint pain, rash—some patients attribute to implants. Outcomes after removal vary by pre-existing disease: patients not meeting rheumatic or autoimmune criteria had >80% physical and 93% psychological improvement; rheumatic but non-autoimmune patients had transient improvement with recurrence at 6–12 months; autoimmune patients showed no improvement and deterioration. A review of 23 studies found 75% of 622 patients noted overall health improvement after removal, but explantation alone helped only 16% with definitive autoimmune disorder. Many with systemic symptoms are referred for rheumatologic evaluation. Patients should be advised of surgical risks and that symptoms may not resolve or may be temporary.

It usually involves the capsule or fluid around the implant. Most cases present as a delayed fluid collection or, less often, a lump near the implant. Cases with reliable surgical histories are linked to textured implant surfaces. Diagnosis is made before surgery using examination, imaging, fluid sampling and special cell tests, and NCCN guidelines guide care. Complete surgical removal has shown better survival than partial capsule removal, chemotherapy or radiation. Evaluation may include bilateral breast examination, ultrasound, seroma aspiration and capsule biopsy. Tumor cells are CD30 positive and ALK negative; specimens should be sent to pathology to rule out ALCL.

Anaplastic large cell lymphoma is a rare lymphoma reported in patients with breast implants, with an estimated risk of 0.1 to 0.3 per 100,000. It usually presents as a seroma after one year and is typically indolent. Treatment by implant removal and capsulectomy is effective, and adjuvant radiation or chemotherapy is not routinely recommended. The exact nature of the association is under active investigation, and no deaths have been reported from this rare entity. Other very rare capsule cancers, such as BIA-SCC, and systemic symptoms some patients attribute to implants are also discussed as possible risks. FDA-approved implants undergo extensive testing, and the vast majority of people with implants experience no serious complications.

BIA-ALCL is a rare T-cell lymphoma linked to the capsule or fluid around a breast implant, and it is predominantly associated with textured implants, although it is premature to conclude it cannot occur with smooth implants. It most often appears as a delayed periprosthetic fluid collection, in about two-thirds of cases, or as a capsular mass in about one-third; lymph node involvement occurs in about one in eight. A seroma presenting more than one year after implant placement should raise concern and prompt investigation. Other possible signs include breast enlargement, skin rash, capsular contracture, pain, swelling or asymmetry. Diagnosis should be made before surgery, using imaging and pathology testing for CD30.

BIA-ALCL grows in the fluid or scar capsule around an implant, whereas primary breast lymphoma involves breast tissue. It is a lymphoma of immune cells, not a carcinoma of breast ducts or lobules. It may appear as late swelling more than one year after implantation, a lump near the implant, pain or asymmetry. Most cases are found during implant revision for a persistent late seroma. Diagnosis should come before surgery, using ultrasound or a scan with a needle sample, and specimens are checked for the CD30 marker. Confirmed disease is treated by removing both implants, the whole capsule and any involved lymph nodes.

BIA-ALCL is a rare T-cell lymphoma that develops around textured breast implants. No cases are uniquely associated with smooth implants, and no single cause is known; inflammation, possible bacterial biofilm and the degree of texturization have been implicated. The risk largely depends on textured implant type. Reported incidence ranges from about 1 in 30,000 women with textured implants to 1 in 3,817–30,000, with higher rates for some recalled textured types. It often presents years later as a late fluid collection, capsular contracture or mass. Diagnosis uses fluid aspiration with CD30 and cytology; treatment includes implant removal, complete capsulectomy and oncology referral, and early management usually results in complete cure.

The vast majority of people with breast implants experience no serious complications, and BIA-SCC is listed among very rare implant-related cancers rather than common problems. Fully informed consent for breast augmentation includes discussing implant-related complications such as BIA-SCC, alongside BIA-ALCL and breast implant illness. The evidence supports awareness and timely consultation if concerns arise, not predicting any individual risk, and it does not provide an individual risk estimate. It is not a routine outcome of augmentation. Prompt review matters if symptoms or changes appear. If a complication develops or you want implant removal for any reason, consult a plastic surgeon. Dr. Vishal Purohit can discuss this during consultation.

Breast implant-associated anaplastic large cell lymphoma and squamous cell carcinoma are very rare cancers in the capsule around the implant, not an increased risk of ordinary breast cancer. These rare cancers occur in the capsule around the implant, not in the breast tissue itself. Epidemiologic studies show implants are not associated with increased risk of carcinomas or other benign or malignant breast tumors, and some studies found lower-than-expected breast cancer incidence. Silicone is not carcinogenic in humans, and a woman’s breast cancer risk is not affected by implants. The rodent Oppenheimer effect has never been observed in humans. Rare breast cancer after augmentation in transgender patients has been linked to prolonged hormonal reassignment therapy.

These cancers are uncommon and may appear years after surgery. BIA-ALCL is mainly linked to textured implants, though it is premature to say it cannot occur with smooth implants. It may present with sudden breast swelling, fluid around the implant, a palpable mass or lymph node enlargement. A spontaneous seroma more than one year after surgery is especially suspicious; late seroma is rare and occurs at least 12 months after surgery. The estimated BIA-ALCL risk with textured implants in the United States is 1:913. Diagnosis requires testing of peri-implant fluid or tissue, including markers such as CD30. The FDA reports rare squamous cell carcinoma and other lymphomas in the capsule, but does not recommend removing asymptomatic implants solely for concern.

Breast cancer is not more common in women with implants; one source says the rate is no greater than the general population, and multiple studies refuted early concerns about silicone implants and breast cancer. Any apparent lower risk may reflect confounding factors such as smaller breast size. Implant-associated anaplastic large cell lymphoma and squamous cell carcinoma are recognized but uncommon risks, and most people with implants have no serious complications. Removal is considered for known or suspected rupture, painful capsular contracture, poor surgical results, or breast cancer treatment, not routine prevention. If you have no symptoms, observation is usually appropriate; consult your surgeon for concerns. Removal decisions should be individualized after assessment.

Multiple epidemiologic studies have not shown an increase in breast cancer after breast augmentation, and silicone has not been associated with increased breast cancer incidence. Implants may raise practical concerns about examination, imaging sensitivity or biopsy access, but they do not delay detection. A separate, very rare concern is BIA-ALCL or other rare cancers in the capsule around the implant, which is not the same as breast cancer. Your individual risk still depends on age, family history and other factors, so screening should continue as advised. Implants do not replace routine mammography or clinical breast examination, and any new lump, swelling, pain or asymmetry should be assessed promptly.

A meta-analysis of the largest group of studies found no significantly increased risk of any specific connective-tissue disease, all definite connective-tissue diseases combined, or other autoimmune or rheumatic conditions. Gabriel et al. followed 749 women with implants for 7.8 years, and Sanchez-Guerrero et al. studied 1,183 Nurse Health Study cohort members with implants for 9.9 years; both found no increased risk. In more than 55,000 subjects, multivariate analysis showed a relative risk of 1.39 (95% CI 0.82–2.35) for confirmed connective tissue diseases, not a large increase. A 32-study meta-analysis suggested possible increased risks for some conditions, but authors called the evidence inconclusive because studies were rarely adequately adjusted for confounders such as smoking or age.

Lactation is usually not permanently impaired, especially when extensive dissection through breast parenchyma is avoided. Women who have had augmentation surgery have a higher incidence of lactation insufficiency than nonaugmented women. Patients should refrain from breast augmentation within six months of lactation to prevent milk pooling within the breast pocket. Good surgical technique and proper postoperative management can minimize, but not always avoid, complications that may result in insufficient milk production. This record does not report an effect on conception or ovarian function; the supported concern is breastfeeding after surgery. Implant placement and incision choice are individualized during consultation. If future breastfeeding matters to you, discuss timing and technique before surgery.

Long-term monitoring guidelines are complex and frequently changing. For cosmetic augmentation, evidence and recommendations vary by implant type, symptoms and history. Recommendations may differ for reconstructive cases. One described protocol examines patients weekly for two weeks, then at one, two, six and twelve months, then annually, with silicone implant imaging from five years and every two years thereafter, starting with ultrasound and MRI if equivocal. Another source recommends weekly self-examination and follow-up for changes in firmness, appearance, nodules or irregularities, with MRI possibly indicated after long-term implantation. No absolute recommendation for when implants should be exchanged is given. Your surgeon can individualize follow-up based on your symptoms and implant type.